Advanced malignant tumor
Conditions
Interventions
Observational group:None
Sponsors
Tianjin First Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years; 2. ECOG score 0-2; 3. Diagnosed as advanced malignant tumor by histological or cytological examination and imaging, all at stage IV; 4. With objectively measurable lesions according to RECIST 1.1 criteria; 5. With clear pre-treatment imaging evidence and tumor marker results before initial anti-tumor treatment; 6. Able to regularly receive anti-tumor treatment and achieve complete remission (CR) or partial remission (PR) as evaluated by imaging; 7. After treatment response, there was a significant increase in tumor markers, but imaging evaluation remained stable; 8. Participants voluntarily joined this study and signed the informed consent form; 9. Subjects with an estimated survival time of >= 3 months.
Exclusion criteria
Exclusion criteria: 1. Subjects whose imaging evaluations show continuous progression after anti-tumor treatment; 2. Subjects with contraindications to follow-up CT/MRI examinations; 3. Subjects who refused to undergo follow-up or failed to do so; 4. Subjects with unstable systemic coexisting diseases (active infection, moderate to severe chronic obstructive pulmonary disease, poorly controlled hypertension, unstable angina pectoris, congestive heart failure, myocardial infarction within 6 months, cerebrovascular accident, pulmonary embolism or untreated grade 3 deep vein thrombosis (DVT) in the past, severe mental disorders requiring medication control, liver, kidney or other metabolic diseases, neuro-psychiatric disorders such as Alzheimer's disease); 5. Subjects whose accompanying diseases, as judged by the investigator, pose a serious threat to the patient's safety or affect the patient's ability to complete the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The sensitivity and specificity of UCAD test results surpass those of tumor markers in the detection of minimal residual lesions across various cancers;The sensitivity and specificity of UCAD test results are prioritized over imaging in monitoring tumor recurrence; | — |
Secondary
| Measure | Time frame |
|---|---|
| Chromosomal instability in peripheral blood cfDNA can serve as an independent prognostic factor for dynamic MRD monitoring in pan-cancer patients after achieving complete remission, significantly correlating with patient survival outcomes including PFS and OS; | — |
Countries
China
Contacts
Public ContactZhao Zhigang
Tianjin First Central Hospital
Outcome results
None listed